SpaceX vs. Rocket Lab: How Do They Compare as Investments?

SpaceX is targeting a $1.77 trillion IPO valuation on $18.7 billion of 2025 revenue, while Rocket Lab trades at about $66 billion on $602 million of revenue. Both companies remain unprofitable and trade at stretched price-to-sales multiples, with key execution risks around SpaceX’s AI losses ($6.4 billion in 2025) and Rocket Lab’s delayed Neutron rocket, which has already pushed first flight to Q4 at the earliest. The article is more comparative and valuation-focused than news-driven, so the likely market impact is limited.

Analysis

The market is being offered two very different scarcity premia: one for a mega-platform with an embedded cash engine, and one for a narrower operating asset with a cleaner path to incremental re-rating. The important second-order effect is that SpaceX’s IPO will likely reset the valuation multiple for every private satellite/launch adjacency, but it may also compress the appeal of public “space beta” names if investors decide they can finally own the category leader directly. That is structurally negative for RKLB as a proxy trade, even if its own fundamentals improve.

RKLB’s setup is more binary and therefore potentially more tradable. Neutron is not just a product launch; it is the gating item for whether the company can graduate from a niche launcher/components story into a credible medium-lift platform with pricing power. If the first flights slip again, the market will likely reprice the stock on an extended cash-burn horizon, not on 2027 revenue ambition, which is why the next 1-2 quarters matter more than the next 2 years.

The contrarian read is that SpaceX may be over-earning its narrative premium while under-earning its actual equity support. If the AI segment remains a cash drain, the IPO could become a “good story, bad hold” situation for public investors: headline TAM will matter less than governance and capital intensity once the lock-up/float expands. Conversely, RKLB’s valuation is easier to justify if Neutron only succeeds partially, because the company already has a functioning revenue base and the market may be underestimating the optionality from components margin expansion rather than just launch success.

The cleanest trading expression is relative value, not outright conviction. The near-term catalyst is Neutron progress versus further delay; the medium-term catalyst is whether public-market enthusiasm for space remains concentrated in the leader or spills into the listed peer group. The biggest tail risk is that both names stay expensive but ill-supported by earnings, causing a broad de-rating if growth decelerates or capital needs rise.

Key Decisions for Investors

• Short RKLB into post-IPO SpaceX debut strength; cover on any confirmed Neutron launch milestone. Timeframe: 2-8 weeks. Thesis: proxy premium should fade once investors can own the category leader directly.
• Pair trade: long SpaceX on IPO if accessible / short RKLB as relative-value hedge. Timeframe: 1-3 months. Risk/reward: favors the business with an actual operating profit engine, but size the short lightly because RKLB has cleaner downside asymmetry if Neutron slips.
• Buy RKLB puts or put spreads into the next Neutron catalyst window. Timeframe: 30-90 days. Best if implied volatility remains below realized volatility; structure for a drawdown on any schedule miss or test failure.
• Avoid chasing SpaceX on day-one IPO prints unless there is a post-lock-up or post-initial-flush dislocation. Timeframe: first 1-3 months after IPO. Reason: governance overhang plus capital intensity makes it vulnerable to a “great company, poor entry” outcome.
• For fundamental exposure to the broader space theme, prefer waiting for a pullback in RKLB rather than paying for momentum. If Neutron works, re-rate can happen over quarters; if it slips, valuation can compress 20-30% quickly.